BASF acquires global leader in omega-3 fatty acids
BASF announced the acquisition of Equateq Ltd., a global leader in the manufacturing of highly concentrated omega-3 fatty acids. With the acquisition, BASF extends its portfolio of omega-3 products for the pharmaceutical and dietary supplement industries with a new offering of highly concentrated omega-3 fatty acids. “We are further strengthening our position as a leading supplier of ingredients for the nutrition and health industries,” said Walter Dissinger, President of BASF’s Nutrition & Health division.

Production site of Equateq on the Isle of Lewis in the Outer Hebrides in Scotland, UK.
Equateq has a production site located on the Isle of Lewis in Scotland with 47 employees. Equateq with all its employees will be integrated into the Pharma Ingredients & Services unit, which is part of BASF’s Nutrition & Health division. The integration is expected to be completed by the end of 2012. The companies have agreed not to disclose financial details of the transaction.
Unique technology for customized fatty acid production
Equateq’s proprietary chromatographic separation methods allow flexible formulation of omega-3 fatty acids at exceptional purity levels. “Equateq’s technologies will enable us to customize fatty acid concentrates with variable ratios of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) at concentration levels of up to 99 percent purity. This is unique in the market,” explained Martin Widmann, Senior Vice President, Pharma Ingredients & Services at BASF.
Growing market for omega-3 fatty acids
BASF believes that highly concentrated omega-3 fatty acids are a global growing market. Increasing consumer awareness of the health benefits of omega-3 is fueling double-digit growth for omega-3 products in the years to come. At the end of 2011 BASF Plant Science announced an agreement with Cargill, an international producer and marketer of food, to co-develop a new dietary source of EPA/DHA omega-3 fatty acid available by the end of the decade.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Finger-trap tension stabilizes cells' chromosome-separating machinery - Accurate gene distribution during cell division depends on stable set-up

New research sheds light on neuronal communication
List_of_subjects_in_Gray's_Anatomy:_III._Syndesmology
Children's ability to detect sugar varies widely
Egg meets sperm: The female side of the story
Teva announces successful results of Phase III with oral laquinimod for multiple sclerosis
Molecule determines friendships
AI driven biopharmaceutical startup raises $10M in series A financing

Single-cell technology: Targeted printing - Bright prospects for personalized medicine

I was here first! This is how hepatitis C inhibits hepatitis E - A single protein from one virus can prevent infection with another virus in cell culture
BAC signs license agreement with Hematech
